Management of Refractory Anaphylaxis: An Overview of Current Guidelines. (2024)

Peer-Reviewed Study · Pouessel G, Dribin TE, Tacquard C, Tanno LK, Cardona V, Worm M, Deschildre A, Muraro A, Garvey LH, Turner PJ · June 12, 2024

Pouessel G et al., 2024-06-12: Overview of international guidelines for refractory anaphylaxis noting that there is a paucity of data behind the existing recommendations.

There is a paucity of data supporting existing management guidelines.

Pouessel G et al., 2024-06-12: Overview of international guidelines for refractory anaphylaxis noting that there is a paucity of data behind the existing recommendations. C10. Study type: comparative review of guidelines (Clin Exp Allergy 2024;54:470-488); Children's Hospital, Roubaix, France. No patients. Records that evidence for refractory-anaphylaxis management is thin and that research priorities remain – relevant because methylene blue use in anaphylaxis rests on case reports, not guidelines. Methylene blue is not named in the abstract captured, hence PARTLY/MEDIUM. Funder/conflicts not stated. Study type: review.